-
EP3490553
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3490553
| EP3490553 - COMBINATION COMPRISING AN INDOLINONE COMPOUND AND ITS USE IN THE TREATMENT OF LYMPHOMA [Right-click to bookmark this link] | |||
| Former [2019/23] | USES OF INDOLINONE COMPOUNDS | ||
| [2024/15] | Status | Grant of patent is intended Status updated on 20.03.2024 Database last updated on 20.05.2024 | |
| Former | Examination is in progress Status updated on 04.08.2022 | ||
| Former | Request for examination was made Status updated on 03.05.2019 | ||
| Former | The international publication has been made Status updated on 03.02.2018 | Most recent event Tooltip | 20.03.2024 | New entry: Communication of intention to grant a patent | Applicant(s) | For all designated states Oncternal Therapeutics, Inc. 3525 Del Mar Heights Road, 821 San Diego, CA 92130-2122 / US | [2019/23] | Inventor(s) | 01 /
LANNUTTI, Brian C/o Oncternal Therapeutics Inc. 3525 Del Mar Heights Road 821 San Diego CA 92130-2122 / US | 02 /
JESSEN, Katayoun C/o Oncternal Therapeutics Inc. 3525 Del Mar Heights Road 821 San Diego CA 92130-2122 / US | 03 /
BREITMEYER, James, Bradley C/o Oncternal Therapeutics Inc. 3525 Del Mar Heights Road 821 San Diego CA 92130-2122 / US | [2019/23] | Representative(s) | Lavoix Bayerstraße 83 80335 München / DE | [N/P] |
| Former [2019/23] | Lavoix Bayerstrasse 83 80335 München / DE | Application number, filing date | 17835216.7 | 26.07.2017 | [2019/23] | WO2017US43979 | Priority number, date | US201662368707P | 29.07.2016 Original published format: US 201662368707 P | US201662417572P | 04.11.2016 Original published format: US 201662417572 P | US201662422504P | 15.11.2016 Original published format: US 201662422504 P | US201662426107P | 23.11.2016 Original published format: US 201662426107 P | US201762503238P | 08.05.2017 Original published format: US 201762503238 P | US201762534067P | 18.07.2017 Original published format: US 201762534067 P | [2019/23] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018022771 | Date: | 01.02.2018 | Language: | EN | [2018/05] | Type: | A1 Application with search report | No.: | EP3490553 | Date: | 05.06.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.02.2018 takes the place of the publication of the European patent application. | [2019/23] | Search report(s) | International search report - published on: | KR | 01.02.2018 | (Supplementary) European search report - dispatched on: | EP | 26.02.2020 | Classification | IPC: | A61K31/404, A61K31/454, A61K39/395, A61K45/06, A61P35/00, A61P35/02, A61K31/635 | [2024/15] | CPC: |
A61K31/404 (EP,CN,KR,US);
A61K31/4155 (EP,US);
A61K31/4184 (CN);
A61K31/4439 (EP,US);
A61K31/454 (CN,KR);
A61K31/475 (CN);
A61K31/496 (EP,US);
A61K31/497 (CN);
A61K31/519 (CN);
A61K31/5377 (EP,CN,US);
A61K31/551 (EP,US);
A61K31/69 (CN);
A61K38/05 (CN);
A61K39/395 (KR);
A61K39/39558 (EP,US);
A61K45/06 (EP,CN,KR,US);
A61P35/00 (EP,CN);
A61P35/02 (EP,CN);
C07K16/2887 (EP,US);
A61K2300/00 (KR);
C07K2317/24 (US);
C07K2317/73 (EP,US)
(-)
| C-Set: |
A61K31/404, A61K2300/00 (US,CN,EP);
A61K31/4155, A61K2300/00 (US,EP);
A61K31/4184, A61K2300/00 (CN);
A61K31/4439, A61K2300/00 (US,EP);
A61K31/454, A61K2300/00 (CN);
A61K31/475, A61K2300/00 (CN);
A61K31/496, A61K2300/00 (EP,US);
A61K31/497, A61K2300/00 (CN);
A61K31/519, A61K2300/00 (CN);
A61K31/5377, A61K2300/00 (EP,US);
A61K31/69, A61K2300/00 (CN);
A61K38/05, A61K2300/00 (CN); |
| Former IPC [2020/13] | A61K31/404, A61K31/454, A61K39/395, A61K45/06, A61P35/00, A61P35/02 | ||
| Former IPC [2019/23] | A61K31/404, A61K31/454, A61K39/395, A61K45/06 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/23] | Title | German: | KOMBINATION MIT EINER INDOLINONVERBINDUNG UND DEREN VERWENDUNG BEI DER BEHANDLUNG VON LYMPHOMEN | [2024/15] | English: | COMBINATION COMPRISING AN INDOLINONE COMPOUND AND ITS USE IN THE TREATMENT OF LYMPHOMA | [2024/15] | French: | COMBINAISON COMPRENANT UN COMPOSÉ INDOLINONE ET SON UTILISATION POUR LE TRAITEMENT DU LYMPHOME | [2024/15] |
| Former [2019/23] | VERWENDUNG VON INDOLINONVERBINDUNGEN | ||
| Former [2019/23] | USES OF INDOLINONE COMPOUNDS | ||
| Former [2019/23] | UTILISATIONS DE COMPOSÉS D'INDOLINONE | Entry into regional phase | 27.02.2019 | National basic fee paid | 27.02.2019 | Search fee paid | 27.02.2019 | Designation fee(s) paid | 27.02.2019 | Examination fee paid | Examination procedure | 27.02.2019 | Examination requested [2019/23] | 10.09.2020 | Amendment by applicant (claims and/or description) | 03.08.2022 | Despatch of a communication from the examining division (Time limit: M06) | 31.01.2023 | Reply to a communication from the examining division | 21.03.2024 | Communication of intention to grant the patent | Fees paid | Renewal fee | 15.07.2019 | Renewal fee patent year 03 | 14.07.2020 | Renewal fee patent year 04 | 15.07.2021 | Renewal fee patent year 05 | 15.06.2022 | Renewal fee patent year 06 | 14.06.2023 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2014168975 (PHARMACYCLICS INC [US], et al) [Y] 1-7,10-25 * ABT199, rituximab, lenalidomide * * claims 1-3, 10, 26-29 * * claims 1-3 * * paragraphs [0219] - [0261] *; | [Y]WO2014173241 (REN BO [CN], et al) [Y] 1-25 * claims 1-17 * * paragraphs [0015] , [0 97] - [0100] * * paragraphs [0277] - [0280] * * last compound; page 84, column first *; | [Y]WO2015018521 (ONCOETHIX SA [CH], et al) [Y] 1-9,14-25 * OTX015;; claims 1-3 * * paragraphs [0170] - [0177] *; | [Y]US2015158846 (CRAWFORD JAMES JOHN [US], et al) [Y] 1-7,10-25 * ABT199, rituximab, lenalidomide;; claims 30-32, 34-35, 40 *; | [Y]WO2016030509 (ONCOETHIX GMBH [CH]) [Y] 1-9,14-25 * claims 1-4, 17-20 * * paragraphs [0113] - [0116] ** examples 8-10 * | International search | [Y]US2011236428 (KIRK CHRISTOPHER J [US], et al) [Y] 1, 27 * See claims 1, 15, 33-35. *; | [Y]WO2013155341 (UNIV GEORGETOWN [US]) [Y] 1, 27 * See claims 1, 10, 21; and paragraphs [0003], [0126], [0141]. *; | [Y]WO2014015153 (STAR BIOTECHNOLOGY LLC [US]) [Y] 1, 27* See claims 1, 8. *; | [Y]US2015297590 (FULTZ KIMBERLY ELIZABETH [US], et al) [Y] 1, 27 * See claims 1, 3, 6. *; | [Y]WO2016057698 (TOKALAS INC [US]) [Y] 1, 27 * See claims 1, 6, 13, 16, 21; and pages 1, 12, 25, 26. *; | [Y] - TOSSO, P. N. et al., "Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing' s sarcoma", Journal of Medicinal Chemistry, (20140000), vol. 57, no. 24, pages 10290 - 10303, XP055459686 [Y] 1, 27 * See abstract; figure 1; and Scheme 1. * DOI: http://dx.doi.org/10.1021/jm501372p | by applicant | - BALAMUTH, NJWOMER, RB., Lancet Oncology, (20100000), vol. 11, pages 184 - 192 | - HYARIYE N ERKIZAN et al., Nature Medicine, (20090000), vol. 15, no. 7, pages 750 - 756 | - HELMAN LJMELTZER P, "Mechanisms of sarcoma development", Nat Rev Cancer, (20030000), vol. 3, no. 9, pages 685 - 94 | - PUI CH et al., N Engl J Med, (20040000), vol. 350, no. 15, pages 1535 - 48 | - CHENG YLEGALL TOLDFIELD CJ et al., Trends Biotechnol, (20060000), vol. 24, no. 10, pages 435 - 42 | - CAS, no. 202590-98-5 | - CAS, no. 1225037-39-7 |